Novo Nordisk A/S Stock price

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 10:59:43 2024-03-01 EST 5-day change 1st Jan Change
850.9 DKK +3.81% Intraday chart for Novo Nordisk A/S +0.22% +21.89%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site

Financials

Sales 2024 * 285B 41.38B 56.07B Sales 2025 * 339B 49.36B 66.87B Capitalization 3,797B 552B 748B
Net income 2024 * 102B 14.85B 20.11B Net income 2025 * 122B 17.69B 23.97B EV / Sales 2024 * 13.3 x
Net cash position 2024 * 15.97B 2.32B 3.15B Net cash position 2025 * 40.09B 5.83B 7.9B EV / Sales 2025 * 11.1 x
P/E ratio 2024 *
37.1 x
P/E ratio 2025 *
30.7 x
Employees 63,845
Yield 2024 *
1.41%
Yield 2025 *
1.69%
Free-Float 70.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.81%
1 week-0.27%
Current month+3.81%
1 month+9.82%
3 months+22.34%
6 months+33.58%
Current year+21.89%
More quotes
1 week
806.50
Extreme 806.5
852.00
1 month
773.90
Extreme 773.9
861.50
Current year
688.80
Extreme 688.8
861.50
1 year
476.05
Extreme 476.05
861.50
3 years
210.08
Extreme 210.075
861.50
5 years
155.08
Extreme 155.075
861.50
10 years
109.10
Extreme 109.1
861.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 90-12-31
Director of Finance/CFO 53 98-12-31
Chief Tech/Sci/R&D Officer - 15-09-30
Members of the board TitleAgeSince
Director/Board Member 63 15-03-18
Chairman 62 17-03-22
Director/Board Member 68 18-02-28
More insiders
Date Price Change Volume
24-03-01 850.9 +3.81% 3,411,569
24-02-29 819.7 -1.73% 5,761,952
24-02-28 834.1 +0.02% 1,684,926
24-02-27 833.9 -1.21% 3,121,587
24-02-26 844.1 -0.58% 1,783,586

Delayed Quote Nasdaq Copenhagen, March 01, 2024 at 10:59 am

More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes treatment products (78.9%); - rare disease treatment products (11.6%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.; - obesity treatment products (9.5%). Net sales are distributed geographically as follows: Europe/Middle East/Africa (25%), the United States (47.8%), North America (3.6%), China (9.2%) and other (14.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
850.9 DKK
Average target price
785.1 DKK
Spread / Average Target
-7.73%
Consensus
  1. Stock
  2. Equities
  3. Stock Novo Nordisk A/S - Nasdaq Copenhagen
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW